Cargando…

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD

The ability of posttransplant cyclophosphamide (PTCY) to facilitate haploidentical transplantation has spurred interest in whether PTCY can improve clinical outcomes in patients with HLA-matched unrelated donors undergoing peripheral blood stem cell transplantation (PBSCT). We investigated our insti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maurer, Katie, Ho, Vincent T., Inyang, Eno, Cutler, Corey, Koreth, John, Shapiro, Roman M., Gooptu, Mahasweta, Romee, Rizwan, Nikiforow, Sarah, Antin, Joseph H., Wu, Catherine J., Ritz, Jerome, Soiffer, Robert J., Kim, Haesook T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405198/ https://www.ncbi.nlm.nih.gov/pubmed/37156098 http://dx.doi.org/10.1182/bloodadvances.2023009791

Ejemplares similares

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells
por: Maurer, Katie, et al.
Publicado: (2023)

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant
por: Nauffal, Mary, et al.
Publicado: (2022)

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
por: Shapiro, Roman M., et al.
Publicado: (2023)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience
por: Maurer, Katie, et al.
Publicado: (2021)

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
por: Gooptu, Mahasweta, et al.
Publicado: (2022)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease
por: Kim, Haesook T., et al.
Publicado: (2022)

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021)

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
por: Al-Homsi, A. Samer, et al.
Publicado: (2023)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation
por: Kim, Haesook T., et al.
Publicado: (2021)

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation
por: Rambaldi, Benedetta, et al.
Publicado: (2022)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
por: Shapiro, Roman M., et al.
Publicado: (2022)

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
por: Akahoshi, Yu, et al.
Publicado: (2023)

MicroRNA-31 regulates T-cell metabolism via HIF1α and promotes chronic GVHD pathogenesis in mice
por: Wu, Yongxia, et al.
Publicado: (2022)

Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD
por: Bruce, Danny W., et al.
Publicado: (2021)

Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults
por: Vasu, Sumithira, et al.
Publicado: (2022)

ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD
por: Xiao, Zunyu, et al.
Publicado: (2022)

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
por: Ueda Oshima, Masumi, et al.
Publicado: (2023)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias
por: Fierro-Pineda, Juan C., et al.
Publicado: (2023)

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
por: Ho, Vincent T., et al.
Publicado: (2022)

Donor bone marrow–derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice
por: Adams, Rachael C., et al.
Publicado: (2022)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation
por: Metafuni, Elisabetta, et al.
Publicado: (2022)

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis
por: Yu, Xiaoliang, et al.
Publicado: (2023)

Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice
por: Zhang, Xin, et al.
Publicado: (2023)

Efflux capacity and aldehyde dehydrogenase both contribute to CD8(+) T-cell resistance to posttransplant cyclophosphamide
por: Patterson, Michael T., et al.
Publicado: (2022)

Tacrolimus initial steady state level in post-transplant cyclophosphamide based GvHD prophylaxis regimens
por: Yao, Janny M., et al.
Publicado: (2022)

Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects
por: Patterson, Michael T., et al.
Publicado: (2023)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant
por: Jimenez Jimenez, Antonio, et al.
Publicado: (2022)

Single-cell immune profiling reveals a developmentally distinct CD4(+) GM-CSF(+) T-cell lineage that induces GI tract GVHD
por: Piper, Clint, et al.
Publicado: (2022)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation
por: Kekre, Natasha, et al.
Publicado: (2017)

NK cells produce high levels of IL‐10 early after allogeneic stem cell transplantation and suppress development of acute GVHD
por: Chan, Yuen Ling Tracey, et al.
Publicado: (2017)

Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0j68ic3l92hc6vb6bst80ovgog